diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM7681diaendo-7681Research ArticleГенетикаGeneticsФармакогенетика сахароснижающих препаратовPharmacogenetics of hypoglycemic agentsКононенкоИрина ВладимировнаKononenkoIrina Vladimirovna

кандидат медицинских наук, ведущий научный сотрудник отделения программного обучения и лечения Института диабета

MD, PhD

shakhtarina@bk.ruМайоровАлександр ЮрьевичMayorovAleksandr Yuryevich

MD, PhD

education@endocrincentr.ruКокшароваЕкатерина ОлеговнаKoksharovaEkaterina Olegovna

Клинический аспирант, научный сотрудник отделения программного обучения и лечения Института диабета

MD, Assistance Researcher

katekoksharova@gmail.comШестаковаМарина ВладимировнаShestakovaMarina Vladimirovna

MD, PhD, Professor, Correspondence member o the Russian Academy of Sciecnes

nephro@endocrincentr.ruФГБУ Эндокринологический научный центр Минздрава РоссииРоссияEndocrinology Research CentreRussian FederationФГБУ Эндокринологический научный центр Минздрава России; ГБОУ ВПО Первый МГМУ им. И.М. СеченоваРоссияEndocrinology Research Centre; Sechenov First Moscow State Medical UniversityRussian Federation2015131120151842834Copyright © Кононенко И.В., Майоров А.Ю., Кокшарова Е.О., Шестакова М.В., 20152015Кононенко И.В., Майоров А.Ю., Кокшарова Е.О., Шестакова М.В.Kononenko I.V., Mayorov A.Y., Koksharova E.O., Shestakova M.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/7681

Несмотря на увеличение количества классов сахароснижающих препаратов, у 35–40% больных сахарным диабетом 2 типа не удается добиться адекватного гликемического контроля. Одной из причин является генетическая гетерогенность сахарного диабета, что требует различных подходов в лечении, вместе с тем, индивидуальные особенности метаболизма и чувствительности к лекарственным препаратам также влияют на эффективность проводимой терапии. В обзоре представлены результаты фармакогенетических исследований основных сахароснижающих препаратов: метформина, производных сульфонилмочевины, агонистов рецепторов глюкагоноподобного пептида-1, тиазолидиндионов.

Despite the increase in the number of hypoglycemic agents, 35%–40% of patients with diabetes are unable to achieve adequate glycemic control. One of the reasons is the genetic heterogeneity of diabetes mellitus, requiring different treatment approaches; however, the individual metabolic features and sensitivity to drugs also affect the therapeutic effectiveness. The review presents the main results of pharmacogenetic research of several antidiabetic drugs: metformin, sulfonylurea, agonists of glucagon-like peptide-1 and thiazolidinediones.

сахарный диабетфармакогенетикасахароснижающие препараты.diabetes mellituspharmacogeneticshypoglycemic agentsОбзор литературы подготовлен в рамках реализации научной программы, поддержанной грантом Российского научного фонда (проект №14-25-00181).ReferencesГенетический паспорт — основа индивидуальной и предиктивной медицины. / Под ред. В.С. Баранова. — СПб.: Н-Л; 2009. [Geneticheskiy pasport — osnova individual’noy i prediktivnoy meditsiny. Ed. by V.S. Baranov. Saint Petersburg: N-L; 2009.]Генетический паспорт — основа индивидуальной и предиктивной медицины. / Под ред. В.С. Баранова. — СПб.: Н-Л; 2009. [Geneticheskiy pasport — osnova individual’noy i prediktivnoy meditsiny. Ed. by V.S. Baranov. Saint Petersburg: N-L; 2009.]Дедов И.И., Шестакова М.В. Персонализированная терапия сахарного диабета: путь от болезни к больному. // Терапевтический архив. – 2014. – №10 – С. 4-9. [Dedov II, Shestakova MV. Personalized therapy for diabetes mellitus: the path from disease to the patient. Ter. Arkh. 2014;(10):4-9].Дедов И.И., Шестакова М.В. Персонализированная терапия сахарного диабета: путь от болезни к больному. // Терапевтический архив. – 2014. – №10 – С. 4-9. [Dedov II, Shestakova MV. Personalized therapy for diabetes mellitus: the path from disease to the patient. Ter. Arkh. 2014;(10):4-9].Бондарь И.А., Шабельникова О.Ю. Генетические основы сахарного диабета 2 типа // Сахарный диабет. – 2013. – Т. 16. – №4 – C. 11-16. [Bondar’ IA, Shabel’nikova OJ. Genetic framework of type 2 diabetes mellitus. Diabetes mellitus. 2013;16(4):11-16.] doi: 10.14341/DM2013411-16Бондарь И.А., Шабельникова О.Ю. Генетические основы сахарного диабета 2 типа // Сахарный диабет. – 2013. – Т. 16. – №4 – C. 11-16. [Bondar’ IA, Shabel’nikova OJ. Genetic framework of type 2 diabetes mellitus. Diabetes mellitus. 2013;16(4):11-16.] doi: 10.14341/DM2013411-16Pollastro C, Ziviello C, Costa V, Ciccodicola A. Pharmacogenomics of Drug Response in Type 2 Diabetes: Toward the Definition of Tailored Therapies? PPAR Res. 2015;2015:415149. doi: 10.1155/2015/415149Pollastro C, Ziviello C, Costa V, Ciccodicola A. Pharmacogenomics of Drug Response in Type 2 Diabetes: Toward the Definition of Tailored Therapies? PPAR Res. 2015;2015:415149. doi: 10.1155/2015/415149Moore AF, Jablonski KA, McAteer JB, et al. Extension of type 2 diabetes genome-wide association scan results in the diabetes prevention program. Diabetes. 2008;57(9):2503-2510. doi: 10.2337/db08-0284Moore AF, Jablonski KA, McAteer JB, et al. Extension of type 2 diabetes genome-wide association scan results in the diabetes prevention program. Diabetes. 2008;57(9):2503-2510. doi: 10.2337/db08-0284Zhou K, Donnelly LA, Kimber CH, et al. Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes. 2009;58(6):1434-1439. doi: 10.2337/db08-0896Zhou K, Donnelly LA, Kimber CH, et al. Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes. 2009;58(6):1434-1439. doi: 10.2337/db08-0896Christensen MM, Brasch-Andersen C, Green H, et al. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics. 2011;21(12):837-850. doi: 10.1097/FPC.0b013e32834c0010Christensen MM, Brasch-Andersen C, Green H, et al. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics. 2011;21(12):837-850. doi: 10.1097/FPC.0b013e32834c0010Hirst JA, Farmer AJ, Ali R, et al. Quantifying the effect of metformin treatment and dose on glycemic control. Diabetes Care. 2012;35(2):446-454. doi: 10.2337/dc11-1465Hirst JA, Farmer AJ, Ali R, et al. Quantifying the effect of metformin treatment and dose on glycemic control. Diabetes Care. 2012;35(2):446-454. doi: 10.2337/dc11-1465Gloyn AL, McCarthy MI. Genetics in Diabetes. Type 2 Diabetes and Related Traits. Front Diabetes. Basel: Karger; 2014. doi:10.1159/000362475Gloyn AL, McCarthy MI. Genetics in Diabetes. Type 2 Diabetes and Related Traits. Front Diabetes. Basel: Karger; 2014. doi:10.1159/000362475DeGorter MK, Xia CQ, Yang JJ, Kim RB. Drug transporters in drug efficacy and toxicity. Annu Rev Pharmacol Toxicol. 2012;52:249-273. doi: 10.1146/annurev-pharmtox-010611-134529DeGorter MK, Xia CQ, Yang JJ, Kim RB. Drug transporters in drug efficacy and toxicity. Annu Rev Pharmacol Toxicol. 2012;52:249-273. doi: 10.1146/annurev-pharmtox-010611-134529Tkac I, Klimcakova L, Javorsky M, et al. Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes. Diabetes Obes Metab. 2013;15(2):189-191. doi: 10.1111/j.1463-1326.2012.01691.xTkac I, Klimcakova L, Javorsky M, et al. Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes. Diabetes Obes Metab. 2013;15(2):189-191. doi: 10.1111/j.1463-1326.2012.01691.xBecker ML, Visser LE, van Schaik RH, et al. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J. 2009;9(4):242-247. doi: 10.1038/tpj.2009.15Becker ML, Visser LE, van Schaik RH, et al. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J. 2009;9(4):242-247. doi: 10.1038/tpj.2009.15Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50(2):81-98. doi: 10.2165/11534750-000000000-00000Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50(2):81-98. doi: 10.2165/11534750-000000000-00000Christensen MM, Pedersen RS, Stage TB, et al. A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin. Pharmacogenet Genomics. 2013;23(10):526-534. doi: 10.1097/FPC.0b013e328364a57dChristensen MM, Pedersen RS, Stage TB, et al. A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin. Pharmacogenet Genomics. 2013;23(10):526-534. doi: 10.1097/FPC.0b013e328364a57dStocker SL, Morrissey KM, Yee SW, et al. The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacol Ther. 2013;93(2):186-194. doi: 10.1038/clpt.2012.210Stocker SL, Morrissey KM, Yee SW, et al. The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacol Ther. 2013;93(2):186-194. doi: 10.1038/clpt.2012.210GoDarts, Group UDPS, Wellcome Trust Case Control C, et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet. 2011;43(2):117-120. doi: 10.1038/ng.735GoDarts, Group UDPS, Wellcome Trust Case Control C, et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet. 2011;43(2):117-120. doi: 10.1038/ng.735Suzuki K, Yanagawa T, Shibasaki T, Kaniwa N, Hasegawa R, Tohkin M. Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. Diabetes Res Clin Pract.2006;72(2):148-154. doi: 10.1016/j.diabres.2005.09.019.Suzuki K, Yanagawa T, Shibasaki T, Kaniwa N, Hasegawa R, Tohkin M. Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. Diabetes Res Clin Pract.2006;72(2):148-154. doi: 10.1016/j.diabres.2005.09.019.Zhou K, Donnelly L, Burch L, et al. Loss-of-Function CYP2C9 Variants Improve Therapeutic Response to Sulfonylureas in Type 2 Diabetes: A Go-DARTS Study. Clin Pharmacol Ther. 2010;87(1):52-56. doi: 10.1038/clpt.2009.176Zhou K, Donnelly L, Burch L, et al. Loss-of-Function CYP2C9 Variants Improve Therapeutic Response to Sulfonylureas in Type 2 Diabetes: A Go-DARTS Study. Clin Pharmacol Ther. 2010;87(1):52-56. doi: 10.1038/clpt.2009.176Swen JJ, Wessels JA, Krabben A, et al. Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus. Pharmacogenomics. 2010;11(11):1517-1523. doi: 10.2217/pgs.10.121Swen JJ, Wessels JA, Krabben A, et al. Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus. Pharmacogenomics. 2010;11(11):1517-1523. doi: 10.2217/pgs.10.121The Pharmacogenomics Knowledge Base [internet]. Available from: https://www.pharmgkb.org/drugThe Pharmacogenomics Knowledge Base [internet]. Available from: https://www.pharmgkb.org/drugFeng Y, Mao G, Ren X, et al. Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients. Diabetes Care. 2008;31(10):1939-1944. doi: 10.2337/dc07-2248Feng Y, Mao G, Ren X, et al. Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients. Diabetes Care. 2008;31(10):1939-1944. doi: 10.2337/dc07-2248Hamming KS, Soliman D, Matemisz LC, et al. Coexpression of the type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K(+) channel. Diabetes.2009;58(10):2419-2424. doi: 10.2337/db09-0143Hamming KS, Soliman D, Matemisz LC, et al. Coexpression of the type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K(+) channel. Diabetes.2009;58(10):2419-2424. doi: 10.2337/db09-0143Holstein A, Hahn M, Korner A, et al. TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes. BMC Med Genet. 2011;12:30. doi: 10.1186/1471-2350-12-30Holstein A, Hahn M, Korner A, et al. TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes. BMC Med Genet. 2011;12:30. doi: 10.1186/1471-2350-12-30Pearson ER, Donnelly LA, Kimber C, et al. Variation in TCF7L2 Influences Therapeutic Response to Sulfonylureas: A GoDARTs Study. Diabetes. 2007;56(8):2178-2182. doi: 10.2337/db07-0440Pearson ER, Donnelly LA, Kimber C, et al. Variation in TCF7L2 Influences Therapeutic Response to Sulfonylureas: A GoDARTs Study. Diabetes. 2007;56(8):2178-2182. doi: 10.2337/db07-0440Shyangdan DS, Royle P, Clar C et al. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011;(10):CD006423. doi: 10.1002/14651858.CD006423.pub2Shyangdan DS, Royle P, Clar C et al. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011;(10):CD006423. doi: 10.1002/14651858.CD006423.pub2Herzberg-Schafer S, Heni M, Stefan N, et al. Impairment of GLP1-induced insulin secretion: role of genetic background, insulin resistance and hyperglycaemia. Diabetes Obes Metab. 2012;14 Suppl 3:85-90. doi: 10.1111/j.1463-1326.2012.01648.xHerzberg-Schafer S, Heni M, Stefan N, et al. Impairment of GLP1-induced insulin secretion: role of genetic background, insulin resistance and hyperglycaemia. Diabetes Obes Metab. 2012;14 Suppl 3:85-90. doi: 10.1111/j.1463-1326.2012.01648.xWolford JK, Yeatts KA, Dhanjal SK, et al. Sequence Variation in PPARG May Underlie Differential Response to Troglitazone. Diabetes. 2005;54(11):3319-3325. doi: 10.2337/diabetes.54.11.3319Wolford JK, Yeatts KA, Dhanjal SK, et al. Sequence Variation in PPARG May Underlie Differential Response to Troglitazone. Diabetes. 2005;54(11):3319-3325. doi: 10.2337/diabetes.54.11.3319Pan H-J, Reifsnyder P, Vance DE, et al. Pharmacogenetic Analysis of Rosiglitazone-Induced Hepatosteatosis in New Mouse Models of Type 2 Diabetes. Diabetes. 2005;54(6):1854-1862. doi: 10.2337/diabetes.54.6.1854Pan H-J, Reifsnyder P, Vance DE, et al. Pharmacogenetic Analysis of Rosiglitazone-Induced Hepatosteatosis in New Mouse Models of Type 2 Diabetes. Diabetes. 2005;54(6):1854-1862. doi: 10.2337/diabetes.54.6.1854Jacobs RL, Devlin C, Tabas I, Vance DE. Targeted deletion of hepatic CTP:phosphocholine cytidylyltransferase alpha in mice decreases plasma high density and very low density lipoproteins. J Biol Chem. 2004;279(45):47402-47410. doi: 10.1074/jbc.M404027200Jacobs RL, Devlin C, Tabas I, Vance DE. Targeted deletion of hepatic CTP:phosphocholine cytidylyltransferase alpha in mice decreases plasma high density and very low density lipoproteins. J Biol Chem. 2004;279(45):47402-47410. doi: 10.1074/jbc.M404027200Holstein A, Plaschke A, Ptak M, et al. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br J Clin Pharmacol. 2005;60(1):103-106. doi: 10.1111/j.1365-2125.2005.02379.xHolstein A, Plaschke A, Ptak M, et al. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br J Clin Pharmacol. 2005;60(1):103-106. doi: 10.1111/j.1365-2125.2005.02379.xДедов И.И., Смирнова О.М., Кононенко И.В. Значение результатов полногеномных исследований для первичной профилактики сахарного диабета 2 типа и его осложнений. Персонализированный подход. // Сахарный диабет. – 2014. – Т. 17. – №2 – С. 10-19. [Dedov II, Smirnova OM, Kononenko IV. Significance of the results of genome-wide association studies for primary prevention of type 2 diabetes mellitus and its complications. Personalised approach.Diabetes mellitus. 2014;17(2):10-19.] doi: 10.14341/DM2014210-19Дедов И.И., Смирнова О.М., Кононенко И.В. Значение результатов полногеномных исследований для первичной профилактики сахарного диабета 2 типа и его осложнений. Персонализированный подход. // Сахарный диабет. – 2014. – Т. 17. – №2 – С. 10-19. [Dedov II, Smirnova OM, Kononenko IV. Significance of the results of genome-wide association studies for primary prevention of type 2 diabetes mellitus and its complications. Personalised approach.Diabetes mellitus. 2014;17(2):10-19.] doi: 10.14341/DM2014210-19

The authors declare that there are no conflicts of interest present.